Featured 13F manager
Alphabet Inc.
Mountain View, CA 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $99.1B
- 28 Positions
- 2026 Q2
- +2367.2% QoQ
- Top 5 98.5%
Alphabet Inc. files a Form 13F. The latest book is 2026 Q2 at $99.1B, up 2367.2% QoQ, led by Space Exploration ·, Planet Labs Pbc, and Ast Spacemobile.
Portfolio
top 5 98.5% · top 10 99.5%
- SPCX - Space Exploration · CLASS A 95.0%
- PL - Planet Labs Pbc · CL A 1.2%
- ASTS - Ast Spacemobile · CL A 0.8%
- CME - CME Group 0.8%
- ARM — 0.7%
- RVMD - Revolution Medicines 0.5%
- Freshworks · CLASS A 0.2%
- PBLS - Parabilis Medicines 0.1%
- TEM - Tempus Ai · CL A 0.1%
- GTLB - Gitlab · CLASS A 0.1%
- PATH - Uipath · CL A 0.1%
- LIFE - Ethos Technologies · CL A 0.1%
- Other 0.3%
AUM over time
Book
| ASTS - Ast Spacemobile · CL A | 18.22% | Hold | 8,943,486 | $49.08 | $439M |
| PL - Planet Labs Pbc · CL A | 17.21% | Hold | 31,942,641 | $12.98 | $415M |
| ARM — | 11.52% | Hold | 1,960,784 | $141.49 | $277M |
| Metsera | 8.22% | Hold | 3,783,528 | $52.33 | $198M |
| RVMD - Revolution Medicines | 8.01% | Hold | 4,133,277 | $46.70 | $193M |
| Freshworks · CLASS A | 7.92% | Hold | 16,206,643 | $11.77 | $191M |
| TEM - Tempus Ai · CL A | 5.20% | Hold | 1,551,102 | $80.71 | $125M |
| GTLB - Gitlab · CLASS A | 5.10% | Hold | 2,724,712 | $45.08 | $123M |
| PATH - Uipath · CL A | 3.91% | Hold | 7,034,337 | $13.38 | $94M |
| PRME - Prime Medicine | 3.81% | Hold | 16,562,498 | $5.54 | $92M |
| DXCM - Dexcom | 2.90% | Hold | 1,036,937 | $67.29 | $70M |
| MAZE - Maze Therapeutics | 2.60% | Hold | 2,412,471 | $25.93 | $63M |
| BBOT — | 1.36% | Hold | 2,823,126 | $11.58 | $33M |
| FIG - Figma · CLASS A | 0.46% | Hold | 215,582 | $51.87 | $11M |
| GLUE - Monte Rosa Therapeutics | 0.45% | Hold | 1,464,015 | $7.41 | $11M |
| Sana Biotechnology | 0.41% | Hold | 2,812,500 | $3.55 | $10M |
| OSCR - Oscar Health · CL A | 0.38% | Hold | 481,988 | $18.93 | $9M |
| DNTH - Dianthus Therapeutics | 0.34% | Hold | 208,697 | $39.35 | $8M |
| Relay Therapeutics | 0.34% | Hold | 1,568,753 | $5.22 | $8M |
| BEAM - Beam Therapeutics | 0.32% | Hold | 321,604 | $24.27 | $8M |
| Vera Therapeutics · CL A | 0.29% | Hold | 241,264 | $29.06 | $7M |
| LYEL - Lyell Immunopharma | 0.20% | Hold | 293,256 | $16.24 | $5M |
| FHTX - Foghorn Therapeutics | 0.10% | Hold | 500,901 | $4.89 | $2M |
| WGS - Genedx | 0.10% | Hold | 22,711 | $107.74 | $2M |
| TSHA - Taysha Gene Therapies | 0.09% | Hold | 640,882 | $3.27 | $2M |
| Tscan Therapeutics | 0.08% | Hold | 1,077,080 | $1.82 | $2M |
| Holding | 0.08% | Hold | 1,513,644 | $1.25 | $2M |
| Spero Therapeutics | 0.07% | Hold | 889,979 | $1.88 | $2M |
| Tenaya Therapeutics | 0.06% | Hold | 915,705 | $1.62 | $1M |
| Hyperfine · CL A | 0.05% | Hold | 898,720 | $1.45 | $1M |
| Exact Sciences | 0.05% | Hold | 23,205 | $54.71 | $1M |
| AUTL - Autolus Therapeutics | 0.05% | Hold | 698,262 | $1.63 | $1M |
| GUTS - Fractyl Health | 0.04% | Hold | 662,584 | $1.59 | $1M |
| ALEC - Alector | 0.02% | Hold | 175,866 | $2.96 | $521K |
| Quince Therapeutics | 0.01% | Hold | 189,122 | $1.63 | $308K |
| FULC - Fulcrum Therapeutics | 0.01% | Hold | 14,262 | $9.20 | $131K |
| RGEN - Repligen | 0.00% | Hold | 383 | $133.67 | $51K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 28 | $99.1B | +2367.2% | 13F-HR | 8/7/2026 | 000165204426000073 |
| 2026 Q1 | 26 | $4B | +55.7% | 13F-HR | 5/8/2026 | 000165204426000051 |
| 2025 Q4 | 29 | $2.6B | +7.1% | 13F-HR | 2/13/2026 | 000165204426000023 |
| 2025 Q3 | 37 | $2.4B | — | 13F-HR | 11/7/2025 | 000165204425000096 |
About
Alphabet Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2